https://doi.org/10.3349/ymj.2019.60. 2.174 mented in all cases, and not described as a prognostic factor. 10 Since LVI predicted that lymph node metastasis was a prognostic factor in UTUC patients, 18, 19 focusing on node-negative patients might have great significance in discovering high-risk factors in patients with node-negative UTUC. In the present study, we aimed to further validate the prognostic value of LVI in patients with UTUC, especially in those with node-negative UTUC undergoing RNU. Improved understanding of prognostic influence of LVI can help us make better prognostic evaluations and more appropriate regimen of adjuvant chemotherapy.
MAtErIALS And MEtHodS

Ethical approval
The study protocol was approved by ethics committee at our institution. All patients involved in this retrospective study have given written informed consent. We made sure that all samples were anonymous.
Patient selection and follow-up
From 2005 to 2013, 180 patients, who were diagnosed with UTUC and treated with RNU in our institution, were analyzed retrospectively. When lymph node enlargement was doubtable on preoperative CT or enlarged during intraoperative examinations, regional lymphadenectomy was routinely performed without extending lymphadenectomy. Patients with incomplete clinical data, non-UTUC, or distant metastasis were excluded. Finally, 180 patients were enrolled in this study.
The study end was recurrence-free survival (RFS) and cancer-specific survival (CSS) after RNU. Disease RFS was defined as local recurrence and lymph node and/or distant metastasis, except the contralateral upper urinary tract or subsequent bladder recurrences. We defined CSS according to death certificates and results estimated by treating physicians. However, patients who died within 30 days of surgery or before discharge were not included as disease recurrence and cancer-specific death cases.
Pathologic evaluation
All specimens were re-reviewed by two genitourinary pathologists according to standard pathologic procedures, to ensure the validity of pathologic data extraction. Tumor stage was assessed according to the 2018 American Joint Committee on Cancer (AJCC) TNM staging system. Tumor grade was evaluated according to the 2016 World Health Organization grading system. 20 The clinicopathological data of patients included age, history of bladder cancer, tumor stage, tumor grade, lymph node involvement, necrosis, multifocality, and hydronephrosis.
Hematoxylin and eosin (H&E) staining is regularly performed in our institute to identify LVI, which is defined pathologically as the presence of tumor cells within a definite endotheliumlined space without underlying muscular walls both in the intratumoral and peritumoral area, or spaces in vascular lined by plump cells at the peritumoral area (Fig. 1A) . 21 Erythrocytes or fibrin clots in blood vessels, and the lack of smooth muscle or elastic fibers in lymphatic vessels can help pathologists to identify vessels and LVI. Immunohistochemical (IHC) staining is not routinely used to assess LVI, unless two pathologists cannot reach an agreement on the confirmation of LVI in one slide (Fig. 1B) . However, it is difficult to distinguish between vascular and lymphatic invasion due to the difficulty and the lack of reproducibility when using routine light microscopic examinations. Nodal status was assessed by pathologists when lymph nodes were retrieved during operation.
Statistical analysis
Statistical analyses were performed by SPSS v. 16 .0 (SPSS Inc., Chicago, IL, USA). The correlation between LVI and other clinicopathological characteristics was tested by χ 2 test or Fisher's exact test. Survival curve for the presence of LVI was estimated with Kaplan-Meier method, and differences were assessed by log-rank statistic. Univariate and multivariate regression analyses were performed with Cox proportional hazards regression model to explain the impact of LVI on RFS and CSS 
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respectively, or in patients without lymph nodes involvement. The results showed that hazard ratios (HRs) served as relative risks with corresponding 95% confidence intervals (CIs). All reported p values were two-sided, and statistical significance was set at p≤0.05.
rESuLtS
Patient characteristics
Our study included 180 patients with UTUC, consisting of 109 males (60.6%) and 71 females (39.4%). Clinicopathological characteristics are listed in Table 1 . The average age of these 180 patients was 67.2 years (ranging from 39 to 87 years), and the mean follow-up period was 45.4 months (ranging from 3 to 180 months).
Association of LVI with clinicopathological features
LVI, present in 28 patients (15.6%), was significantly associated with advanced pathological stage (p<0.001), tumor necrosis (p=0.012), lymph nodes metastasis (p=0.017), and multifocality (p=0.012) ( Table 1) . Exclusion of lymph node-positive patients did not alter the significant correlation of LVI with advanced pathological stage (p=0.008), tumor necrosis (p= 0.007), and multifocality (p=0.007) (data not shown).
correlation of LVI with clinical prognosis in all patients
LVI was closely associated with RFS and CSS (Tables 2 and 3 
correlation of LVI with clinical prognosis in node-negative patients
The number of patients with node-negative UTUC was 169. In patients without lymph node involvement, the 5 year RFS and 
dIScuSSIon
LVI has been proven to be a significant prognostic factor in various malignancies such as liver, testis, and penile cancer. 12 Some studies have estimated that LVI was a poor prognostic predictor in patients with UTUC after RNU. [10] [11] [12] [13] However, the influence of LVI in prognosis was meaningless in other stud- Fig. 3 . Kaplan-Meier curves of disease RFS (A) and CSS (B) stratified by LVI in 169 patients with node-negative upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. RFS, recurrence-free survival; CSS, cancer-specific survival; LVI, lymphovascular invasion. ies, [15] [16] [17] which remains a controversial problem. In consonance with previous studies, our results indicated that LVI was a poor independent predictor of RFS (p=0.001) and CSS (p=0.001) in UTUC patients. [10] [11] [12] [13] Most node-positive patients with UTUC had early distant metastasis after RNU. 19 Since lymph node involvement was thought as an adverse factor in UTUC, focusing on node-negative patients might have a great significance in discovering the high-risk factors in them. However, only a few studies analyzed the association between LVI and the outcome of patients with node-negative UTUC. In node-negative patients, multivariate analysis suggested that LVI was associated with poor prognosis in RFS (p<0.001) and CSS (p=0.001). Therefore, our study suggested that LVI was also a poor predictor of RFS and CSS in node-negative patients. On this basis, pathologic assessment of UTUC specimens should be routinely recorded for LVI, especially in node-negative ones. In addition, LVI was associated with established features of UTUC, such as advanced pathological tumor stage, presence of tumor necrosis, and multifocality, which are all independent poor prognostic factors. [6] [7] [8] Nowadays, tumor stage is the most important prognostic indicator of UTUC. We acquired the same results that advanced pathological tumor stage was an important prognostic factor in RFS (HR=13.688; 95% CI=5.55-33.755; p<0.001) and CSS (HR=12.782; 95% CI= 4.33-37.756; p<0.001), respectively.
LVI has been involved in TNM classification of some tumors, such as lung cancer, colorectal cancer, gastric cancer, and testicular cancer, [22] [23] [24] [25] which meant that LVI might have a similar significance in TNM classification. In non-small-cell lung cancer (NSCLC), stage IA with vascular invasion (VI) and stage IB had equivalent prognostic outcomes, suggesting that pT IA NSCLC with VI should be upstaged similar to pT IB NSCLC. 22 Ahmed Farag, et al. 23 found that adding LVI to TNM classification of colorectal cancer could help the physician provide more aggressive treatment strategies for patients with early TNM stage with LVI. In nonseminomatous germ cell tumor, stage I patients with LVI were advocated to accept adjuvant chemotherapy compared to patients without LVI advocated to accept surveillance. 25 According to our results, LVI should be evaluated as reference criteria for high risk stratification and included in TNM classification system for UTUC, especially for patients with node-negative UTUC. Further prospective studies should focus more on the influence of LVI on UTUC patients of different TNM stages.
LVI was defined as the presence of tumor cells within an endothelium-lined space of vascular or lymphatic vessels without underlying muscular walls both in the intratumoral and peritumoral area, or spaces in vascular lined by plump cells at the peritumoral area. 21 It is an important step in the mechanisms of tumor growth, lymph node involvement, and distant metastasis. There was no prognostic value of LVI in node-positive patients (data not shown) compared to node-negative ones. LVI and metastatic lymph nodes had a powerful association (p=0.017), which suggested that LVI might be an essential step for lymph node metastasis, and can prompt to seek for occult metastasis during the operation. Therefore, LVI can give a hint about whether or not regional lymph nodes should be removed. While H&E staining has lower diagnostic accuracy in detecting LVI compared with using IHC staining, increasing application of IHC staining could reap more reliable result.
On account of the currently insufficient data of UTUC, the effect of adjuvant chemotherapy in UTUC still remains controversial. 26, 27 Some studies showed that adjuvant chemotherapy improved CSS in patients with node-positive UTUC or positive LVI. 28, 29 Therefore, application of adjuvant chemotherapy should be personalized according to the situation of LVI or lymph node involvement. In node-negative patients with UTUC, the association of LVI with the effect of adjuvant chemotherapy has not been proven. Unfortunately, due to the limitation of sample size, we did not analyze the effect of adjuvant chemotherapy in patients with node-negative UTUC. While our results presented that LVI was a high-risk prognostic factor in node-negative patients with UTUC, it is probably an indicator guiding more accurate administration of adjuvant chemotherapy in node-negative patients.
There are several limitations in our study. First, this study had a single-center retrospective design, which carries an intrinsic bias. Further prospective study in a large-scale population should be performed to explore the prognostic implication of LVI in UTUC. Second, lymph node metastasis was proven as an outcome predictor in other results. 11, 13 We did not verify its prognostic role in our study. This was due to the small size of our enrolled patients, especially the node-positive patients. However, the prognostic implication of LVI in node-negative patients was more importantly and powerfully investigated in our study. Third, the criterion of LVI might have a bias due to the relatively lower accuracy compared to IHC staining. However, the application of IHC staining was limited on the account of its price and other reasons worldwide.
In summary, LVI is an independent adverse prognostic factor in patients with node-negative UTUC after RNU, which is linked to shorter RFS and CSS. LVI can be estimated as a selection criterion for high risk stratification, and help physicians make decisions on accurate administration of adjuvant chemotherapy. LVI should be routinely estimated in histological specimens.
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